Navigation Links
lines in Medical Technology

SF1126, Semafore's PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines

INDIANAPOLIS, Aug. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced data presented at the Seventh International Congress on Targeted Therapies in Cancer in Washington, D.C., showing additional antiangiogenic activity of vascular-targeted PI3 kinase (PI3K) inhibitor SF1126, by blockin...

Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines

HIV-Infected Women and Non-Whites New to Antiretroviral Therapy Respond Similarly to Men and Whites MEXICO CITY, Aug. 5 /PRNewswire-FirstCall/ -- Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease inhibitor Kaletra(R) (l...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

SOMERSET, N.J., July 21 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL ) today announced that a paper published in Molecular Cancer Therapeutics (2008; 7(7):1871-9) reports that a combination of ONCONASE (ranpirnase) and the thiazolidinedione antidiabetic drug rosiglitazone show...

Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines

OMAHA, Neb., April 30 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a global genetic analysis and services company, today announced the National Cancer Institute had approved a proposal to perform mutational analysis and sequencing of the mitochondrial genes in the N...

Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' Cell Lines

ZFN Technology has Broad Applications in Research, Drug Development and Therapeutics ST. LOUIS and RICHMOND, Calif., March 24 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL ) and Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today the pub...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") announces that a poster by Dr. Maureen E. Lane et al. of , New York, entitled "In Vivo Synergy between Oncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116 Xenografts" is scheduled to be presented tod...

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

Study Results Published in Cancer Research TARRYTOWN, N.Y., June 15, 2007 /PRNewswire-FirstCall/ -- EpiCept Corporation today announced the results of scientific studies that (1) demonstrate that Azixa(TM) (MPC-6827) is effective in treating multiple types of human tumors in animal models, (2) rev...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...pplications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com . Abou...

Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity

...YVILLE, Calif., July 17 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public Library of Science One. "In this study we show that ...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

... alone, it demonstrated significant cytolytic activity in 7 of 9 NSCLC cell lines examined. The combinations demonstrated strong synergistic effects on cell ...mbination of reovirus and paclitaxel was invariably synergistic in all cell lines tested, regardless of their level of sensitivity to either agent. The inv...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

...hat is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment. The study is being conducted in two stages, with the first stage initiated in January 2008 and having enrolled 95 patients (47-...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech

... Inc., a wholly-owned member of the Roche Group, for the generation of cell lines with novel characteristics for pharmaceutical protein production purposes u...e need for selection markers, thereby enabling the rapid generation of cell lines in which multiple genes have been knocked out. Our proven ability to quick...

Alfacell Provides Shareholder Update

...enes, we added Onconase to three mesothelioma cell lines at a dose which is achievable in humans, and then ...ses in all of these genes in the mesothelioma cell lines were seen after treatment with Onconase validating...ance to chemotherapy. Moreover, these data in cell lines are complemented by most recent animal study in mi...

Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506

...m of angiogenic pathways, including VEGFR and TIE2. BAY 73-4506 has also been shown in preclinical studies to prevent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these studies is not known ...

Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials

...d attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone ...

In Rare Disorder, a Familiar Protein Disrupts Gene Function

...together they maintain the world's largest database of patients with CdLS. In the current study, Krantz did a genome-wide analysis of mutant cell lines from 16 patients with severe CdLS. All the cells had mutations in the NIPBL gene, which plays a role in moving cohesin onto and off chromosomes. ...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

...d attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone ...

New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns

...ld Fix Standards to Allow Use of Current Stem Cell lines SANTA MONICA, Calif., May 20 /PRNewswire-USNe...ed the NIH to fund research on embryonic stem cell lines that were derived before 9 pm, Aug. 9, 2001. In practice there were about 20 lines that were available to scientists that qualified f...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

...t-generation product that builds on Boston Scientific's long-time leadership in the peripheral interventions market. The Company's peripheral product lines feature technologies used to diagnose and treat peripheral disease, including stents, balloon catheters, sheaths, wires, peripheral embolization solut...

Glycerin Proven to Improve Bruising and Swelling Caused By Trauma to Skin

...company. Headquartered in Mandeville, Louisiana, the company is dedicated to the revitalization of New Orleans, and manufactures the company's product lines at local plants. Dr. Holmquist Healthcare's product line currently features Bruise Relief(TM), a topical skin care product in a gel and serum formulat...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

...BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): a preliminary report. General Poster Session: Lung Cancer - Metastatic." Saturday 30 May ...

CMC ICOS Biologics and Implicit Bioscience Ltd Announce IC14 Antibody Manufacturing Agreement and Patent License

... has negotiated a non-exclusive license to utilize the CMC proprietary CHEF1(R) expression technology, a system that rapidly generates production cell lines and provides the flexibility to quickly increase manufacturing capacity as needed. Both agreements have been structured with an eye to future partner...

Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs

...d attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone ...

Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimer's Treatments

...d attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

...eptors, which are overexpressed in a wide range of cancers. Results from preclinical in vitro and in vivo studies of EP-100 in ovarian cancer cell lines and ovarian xenograft models were presented in a poster presentation entitled, "Targeted Oncolytic Peptide for Treatment of Ovarian Cancers" at the Am...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

...however, a bioabsorbable device is designed to be slowly metabolized by the body and completely absorbed over time. "Abbott has been on the front lines of innovation in stent technology, and the fully bioabsorbable device is on track to become a clinical reality for patients," said John M. Capek, Ph.D...

Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences

...pplications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com . This press...

Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia

... The patient population is defined as Philadelphia chromosome-negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who have previously undergone stem cell transplantation. The rALLy trial is currently being conducted ...

Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound

... The patient population is defined as Philadelphia chromosome- negative adult patients in second relapse, or those patients who relapsed following two lines of anti-leukemia chemotherapy, including those who have previously undergone stem cell transplantation. The rALLy trial is currently being conducted a...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

... the Phase I component and 66 patients in the Phase II component). At the time of this analysis, 73 patients were evaluable for response. Median prior lines of therapy was 5 (range 1 - 13), including; 100% of patients had been treated with bortezomib (50% of the patients were previously treated with at lea...

Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs

...o prevent blindness. "Producing millions of patient-specific stem cell lines is commercially unviable," stated William M. Caldwell, CEO and Chairman of ...em cells banks to match patients. We estimate that a bank of 100 different lines could furnish a complete tissue (HLA haplotype) match for half of the US po...

Oridion Announces Significant Medical Studies Presented at STA

...ere also presented showing the unique Oridion family of CO2 breath sampling lines - FilterLine(R), and how they bring the superior Microstream(R) measuring t...sampling, providing accurate readings compared to other tested CO2 sampling lines with and without oxygen supply, when sampling from nose and mouth breathers...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...r patients were enrolled in a combined Phase 1/2 study (18 patients in the Phase I component and 66 patients in the Phase II component). Median prior lines of therapy was 5 (range 1 - 13), including; 100% of patients had been treated with bortezomib (50% of the patients were previously treated with at lea...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

...rie Brown and colleagues from Children's Hospital of Philadelphia and University of Pennsylvania demonstrated that SGI-1776 inhibited human ALL cell lines in a dose-dependent manner. Furthermore, SGI-1776 and the m-tor inhibitor rapamycin acted synergistically to inhibit ALL cell proliferation. In a clin...

Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma

...ant cells of Hodgkin's lymphoma (HL) as well as other CD30-expressing cancers. MDX-1401 demonstrated almost a doubling in potency and efficacy in cell lines when compared to MDX-060. The improved potency and efficacy of MDX-1401 in in vivo xenograft models indicates enhanced antibody-dependent cellular cyt...

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

...of patients with myeloproliferative disorders. These JAK2 and MP L defects cause the overproduction of mature malignant blood cells, but multiple lines of evidence suggest that these are not the only molecular lesions responsible for abnormalities in the stem cell in these disorders. Greater analysis ...

Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial

...and to operate more simply and quietly. Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate LVAS with more than 12,000 devices implanted in patients suffering from heart fa...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

...g. CompoZr(TM) ZFN reagents can be used to efficiently create modified cell lines and model organisms with precise and heritable gene deletions, insertions o...s ZFN technology as a new approach for rapid generation of "knock-out" cell lines (Santiago et al., 2008, PNAS 105: 5809). Select 2009 Objectives ...

Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand

...able option. Firms have few options to address these issues, and each solution presents significant drawbacks. Building new commercial sterile filling lines for clinical fills in-house is cost prohibitive. Large contract fillers have no financial incentive to service clinical volume-size projects, while sm...

PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru

...d attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone ...
Other Tags
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ... through 2020. Also, a seven-year historic analysis is provided for these ...
(Date:2/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND ... new groundbreaking payment method. Payment accounts may be selected ... be accessed if both the speech (the word associated ...
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2
(Date:3/5/2015)... 05, 2015 Central Nebraska Imaging (CNI) ... including the brand’s new logo and optimized website. ... practice’s modern approach to expert diagnostic imaging, centered on ... be built to be a resource for Nebraska patients ... automated forms, communication and referral functionality, video content and ...
(Date:3/5/2015)... On March 2, 2015, NBC News posted ... Rise, Plastic Surgeons Say,” that comments on the 2014 ... Plastic Surgery and the American Society of ... doubling of surgical butt augmentations performed in 2014. According ... this increase can be attributed to the social impact ...
(Date:3/5/2015)... March 05, 2015 At the ... Beyond,” leaders in addiction treatment met today in Jackson, ... best clinical practices. Among the numerous respected speakers will ... will address the role that pain medications have had ... evidence-based treatment options. , "It is hard to believe ...
(Date:3/5/2015)... 05, 2015 University of Western ... in 1904, has launched a new center of ... changes. The Northwest Center for Lifestyle and Functional ... community outreach, and conduct research in the areas ... and nutrition. The center will target efforts on ...
(Date:3/5/2015)... 2015 Dr. Jonathan Glashow a board ... has been named by Castle Connolly as ... Dr. Glashow has been selected by Castle Connolly Medical ... top specialty care doctors in the tri-state metropolitan New ... program, which carefully screens and selects doctors through a ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
Other Contents